Faeth Therapeutics, Inc. (FTH)
NASDAQ · Healthcare
$28.19+8.97%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $34.81M
- P/E ratio
- —
- EPS
- —
- Volume
- 122,149
- 52-week high
- —
- 52-week low
- —
- Open
- $26.51
- Day high
- $28.99
- Day low
- $25.99
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$21.09M | -$16.72 |
| 2024 | — | -$30.16M | -$24.01 |
| 2023 | — | -$34.1M | -$1.22 |
| 2022 | — | -$48.59M | -$1.58 |
| 2021 | — | -$36.79M | -$1.33 |
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
- CEO
- Anand Parikh
- Employees
- 29
- Country
- US
- IPO date
- Aug 11, 2014
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Faeth Therapeutics, Inc.'s stock price today?
- FTH is trading at $28.19 as of Jul 20, 2026.
- What is Faeth Therapeutics, Inc.'s market cap?
- Faeth Therapeutics, Inc. (FTH) has a market capitalization of $34.81M.
- Does Faeth Therapeutics, Inc. pay a dividend?
- Faeth Therapeutics, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Faeth Therapeutics, Inc. in?
- Faeth Therapeutics, Inc. operates in the Healthcare sector.